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Practice Points: 
- Glaucoma is considered a neurodegenerative disease due to its pathophysiology of 
progressive retina ganglion cell (RGC) and axon degeneration and RGC death, which 
leads to functional impairment and in most severe case, blindness. 
 
- There are multiple approved topical therapies with IOP lowering effects used in the 
treatment of glaucoma. The most common mechanism of these topical treatments is 
to either suppress the production of aqueous humour, or increase the outflow 
pathways. 
 
- Some patients disease progresses despite well-controlled IOPs, demonstrating that 
IOP alone does not explain the pathogenesis of this complex neurodegenerative 
disease. Putative mechanisms include oxidative stress and apoptosis, similar to that 
seen in Alzheimer’s disease.   
 
- There are a small number of commercially available agents for the treatment of 
glaucoma, which have shown promise in possessing potential neuroprotective 
effects. 
 
- Clinical research has an emphasis on: neuroprotection (delaying or preventing the 
apoptosis of RGC’s), and neuro-recovery (reversing the process of RGC apoptosis).  
 
- Important modulatory cascades that can be manipulated are rho-associated coiled 
coil-forming protein kinase, renin-angiotensin system, endothelin, nitric oxide and 
adenosine. 
 
- An explosion of interest has accrued on immune-modulation, stem cell therapy and 
neural regeneration, with exciting developments expected in the not too distant 
future.   
Abstract: 
Glaucoma is a neurodegenerative disease with an estimated prevalence of 60 million 
people, and the most common cause of irreversible blindness worldwide. The mainstay of 
treatment has been aimed at lowering intraocular pressure, currently the only modifiable 
risk factor. Unfortunately, despite adequate pressure control, many patients go on to suffer 
irreversible visual loss. We first briefly examine currently established IOP lowering 
treatments, with a discussion of their roles in neuroprotection as demonstrated by both 
animal and clinical studies. The review then examines currently available IOP-independent 
agents that have shown promise for possessing neuroprotective effects in the management 
of glaucoma. Finally, we explore potential future treatments such as immune-modulation, 
stem cell therapy, and neural regeneration as they may provide further protection against 
the neurodegenerative processes involved in glaucomatous optic neuropathy. 
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Introduction 
Glaucoma, the commonest irreversible cause of blindness worldwide, has an estimated 
prevalence of 60 million people, leading to 8.4 million people with blindness as a result.  
These figures have been projected to increase to 80 million and 11.2 million respectively, by 
2020 [1].  It is a disease with an optic neuropathy characterized by optic disc cupping and 
visual field loss. It has been considered a neurodegenerative disease due to its 
pathophysiology of progressive retina ganglion cell (RGC) and axon degeneration and RGC 
death [2–4], which leads to functional impairment and in most severe case, blindness. 
 
Glaucoma classification can be carried out in different ways, but is most commonly based on 
drainage angle morphology and any secondary causes of the disease. If an elevated 
intraocular pressure (IOP) is present without glaucomatous damage, it is termed ocular 
hypertension (OHT). In the case of glaucoma with low IOP, it is termed normal tension 
glaucoma (NTG). 
 
Currently, most of the treatment modalities are based on lowering the IOP, the only 
successfully modifiable risk factor that has been identified. However, there are some 
patients whose disease progresses despite well-controlled IOPs, demonstrating that IOP 
alone does not explain the pathogenesis of this complex neurodegenerative disease [5,6]. 
These observations suggest that other, non-IOP dependent factors may play a significant 
role in the pathophysiology of glaucoma, and have thus attracted much research in search 
of novel approaches to glaucoma management. 
 
Studies have shown that the glaucoma-associated neurodegeneration process is not limited 
to the optic nerve, but involves the whole visual pathway extending to the lateral geniculate 
nucleus and visual cortex [7–9], as demonstrated by MRI imaging showing a reduction in 
height and volume of the LGN in subjects with POAG [10]  and NTG [11]. Similarly, fMRI 
studies have confirmed alterations in the visual cortex that correlate with the visual field 
changes observed in glaucoma [10,12]. 
 
In this review, we will summarise current treatment modalities of glaucoma, and their links 
to neurodegeneration, as well as possible neuroprotection pathways and current trials 
exploring the management of glaucoma as a neurodegenerative disease. 
 
  
Commonly used anti-hypertensive agents: 
Intraocular pressure is determined by the balance between the aqueous humour synthesis 
and its rate of outflow. Aqueous is produced by the non-pigmented cells of the ciliary body 
epithelium, flowing in a retrograde manner anteriorly through the pupil to the trabecular 
meshwork (TM). The resistance to this outflow pathway at the trabecular meshwork 
increase with age, and can lead to an IOP increase and primary open angle glaucoma 
(POAG).  
 
There are multiple approved topical therapies with IOP lowering effects used in the 
treatment of glaucoma. The most common mechanism of these topical treatments is to 
either suppress the production of aqueous humour, or increase the outflow pathways. The 
major established classes of IOP-lowering drugs are beta-adrenergic blockers (BB), alpha-
adrenergic agonists (AA), carbonic anhydrase inhibitors (CAI), and prostaglandin analogues 
(PGA). 
 
Beta-blockers 
Beta-blockers (BBs) were once the gold standard topical treatment before PGAs, as they 
achieved good IOP-lowering effect with relatively limited ocular side effects. While no 
longer the first line agent in use, BBs are still frequently used as a combination therapy 
agent with other classes of drug. BBs block sympathetic β-adrenocepters on the ciliary 
epithelium and elicit their IOP lowering effect by reducing aqueous production. [13]. This 
treatment may not be suitable for patients with co-existing respiratory and cardiac 
pathology due to the systemic side effects.  
 
Beyond IOP reduction, there is a small body of evidence that BBs may harbour IOP 
independent neuroprotective effects, perhaps through up-regulation of brain derived 
neurotrophic factor (BDNF) [14,15], or by modulation of vasculature which may temper 
ischemia-induced RGC injury [16]. 
 
Prostaglandin Analogues 
Clinically, Prostaglandin Analogues (PGAs) have become the first line treatment 
recommended by national guidelines, due to the advantages of once-daily administration 
and relatively low side-effect profile [17]. Most PGAs used in the treatment of glaucoma are 
PG F2α analogues, which act via the G protein-coupled receptor family to stimulate aqueous 
outflow by several fold via the uveoscleral pathway [18]. Bimatoprost, Latanopost, and 
Travorpost have been shown to increase uvealscleral outflow in different groups of 
glaucoma patients, including ocular hypertension, HTG and NTG [19–22].  
 
Although a handful of in vitro animal studies have suggested PGAs to exhibit a direct and 
IOP independent neuroprotective effect in RGCs by reducing apoptosis [23–25], no other 
supporting evidence for this has been published. 
 
Carbonic Anhydrase Inhibitors 
Carbonic Anhydrase Inhibitors (CAIs) reduce IOP by inhibiting carbonic anhydrase, a critical 
enzyme required for aqueous humour production, noncompetitively and reversibly at the 
ciliary body epithelium in the posterior chamber. Their action leads to a reduction of 
bicarbonate ions, hence reducing sodium and fluid transportation, and aqueous formation 
[26]. Both topical and oral preparations are used in the management of glaucoma.  
 In addition to their IOP lowering properties, CAIs have also been shown to improve blood 
flow in the retina due to vasodilatory effects which lead to increased retrobulbar blood flow 
[27,28]. Although the reduction of optic nerve head circulation has been demonstrated in 
both POAG and NTG patients [29], there is no evidence that the vasodilatory effect of CAIs 
produces any additional neuroprotective effect independent of IOP. 
 
Currently available agents with potential neuroprotective effects: 
There are a small number of commercially available agents for the treatment of glaucoma, 
which have shown promise in possessing potential neuroprotective effects. 
 
Brimonidine: 
Brimonidine is a highly selective alpha2- adrenergic agonist that was approved by the FDA 
for the treatment of glaucoma in 1996. It acts to suppress aqueous formation by adenylate 
cyclase inhibition, and to increase uveoscleral outflow by increasing prostaglandin release 
via alpha adrenergic stimulation [30]. Interestingly, beyond the glaucoma drainage 
apparatus, α2-receptors have also been localised in other ocular sites such as human 
cadaveric iris and ciliary epithelium [31], as well as in neuronal dendrites, glia, ciliary muscle, 
retina, retinal pigment epithelium, and the choroid of animal eyes [32]. 
 
There has been a strong interest in the neuroprotective actions of Brimonidine, as it is the 
only topical glaucoma treatment to have shown a promising neuroprotective effect in 
human clinical trials [33]. In the Low-pressure Glaucoma Treatment Study (LoGTS) involving 
178 NTG patients, a similar IOP lowering effect was achieved with Brimonidine (14.2 mmHg, 
SD=1.9) and timolol 0.5% (14.0 mmHg, SD=2.6). When analysing visual field (VF) progression 
after four years of treatment however, the authors found that a significantly smaller 
proportion of the Brimonidine group had VF progression than the Timolol group (9.1% vs 
39.2%). This remarkable increased preservation of visual function exhibited by the 
Brimonidine group implies an IOP independent mechanism for Brimonidine’s action. It must 
be said however that ocular allergy to Brimonidine resulted in significantly higher rates of 
participant dropout in this group in the first year, which could have masked visual field 
progression in this group of patients which were not analysed [34]. This higher incidence of 
ocular allergy also means that any potential protective effect from Brimonidine is only 
possible for patients who can tolerate the agent.  
 
Multiple in vitro studies have confirmed Brimonidine to be protective against excitotoxic 
insults to RGCs [35–37]. It has also been shown to protect RGCs against Glutamate mediated 
excitotoxicity by reducing cAMP dependent intracellular calcium accumulation [38]. In vivo 
studies have also demonstrated Brimonidine’s neuroprotective effects; in a rat glaucoma 
model, intravitreal Brimonidine was found to significantly increase BDNF concentrations in 
RGCs, a finding that is perhaps unsurprising due to the multiple ocular sites with alpha-2 
adrenergic receptors expression [39]. Other animal studies have also demonstrated 
Brimonidine’s RGC protection properties in the face of different retinal and optic nerve 
insults such as ischaemia and optic nerve compression [40,41]. A recent study by our group 
found Brimonidine to significantly reduce RGC apoptosis in vitro, and in vivo glaucoma 
models through its effects on the amyloid beta pathway [37].  
 
Beyond action at the RGC level, anterograde optic nerve axonal transport to the superior 
colliculus was shown to be restored by Brimonidine in a rat glaucoma model [42]. As axonal 
dysfunction and degeneration precede neuronal loss [43,44], these supplementary 
protective mechanisms instigated by Brimonidine may explain its additional IOP 
independent benefits in preventing visual field progression in adult subjects [33]. 
 
Coenzyme Q10  
Coenzyme Q10 (Co-Q10) is a co-factor of the mitochondrial electron transport chain, playing 
an important role in mitochondrial gene expression, mitochondrial DNA maintenance, and is 
essential for adenosine triphosphate (ATP) synthesis [45]. As well as being a potent anti-
oxidant, Co-Q10 is thought to prevent the formation of mitochondrial permeability 
transition pores [46], which are known to be a pro-apoptotic trigger in RGC death following 
excitatory damage [47]. As such, Co-Q10 has been reported to show neuroprotective effect 
in other neurodegenerative diseases, such as in Alzheimer’s disease (AD) and Parkinson’s 
disease (PD) [48]. 
 
Many animal studies have provided promising results for Co-Q10’s neuroprotective effects 
in glaucoma models; It has been demonstrated that intraocular and oral Co-Q10 reduces 
RGC apoptosis [49], and ameliorates oxidative stress mediated mitochondrial dysfunction in 
a rat OHT model [50]. Co-Q10 can also reduce damage from glutamate excitotoxity, and 
promote RGC survival by preserving optic nerve head axons in glaucomatous mice [51]. 
 
A single human clinical has studied the effects of topical Co-Q10 with vitamin E in POAG 
patients at 1 year using retinal-evoked, and cortical-evoked responses as a measure of visual 
function [52]; the study found that Co-Q10 with vitamin E administration resulted in 
significantly enhanced inner retinal function (as demonstrated on pattern electroretinogram  
(PERG) readings), with consequent improvements of the visual cortical responses (as 
measured by visual evoked potentials (VEP)) when compared to the control group. More 
over, theses improvements were seen to be independent of age, IOP, and VF changes, 
confirming these effects to be due to the Co-Q10/vitamin E supplementation [52]. 
 
Citicoline 
Citicoline is a major phospholipid in the neuronal membrane that has a crucial role in 
phosphatidylcholine synthesis [53]. It is also thought to play a role in increasing the 
metabolism of cerebral structures via facilitating the biosynthesis of phospholipids in 
neuronal membranes [54], and inhibiting phospholipid degradation [53]. In vitro studies 
have previously reported data supporting Citicoline’s protective effects against apoptosis, 
and reducing synaptic loss in retinal cell cultures [55,56]. Due to these features, Citicoline 
has been shown to have a neuroprotective effect in conditions such as stroke [57,58] and 
PD [59].  
 
Randomised controlled trials of intramuscular [54] and topical Citicoline [60] vs placebo in 
glaucoma patients have demonstrated a significant improvement in retinal function as 
measured by electrodiagnostics; VEP and PERG were measured as they reflect retinal 
bioelectric responses and visual cortical responses respectively. Citicoline treatment was 
found to result in significant improvement in VEP and PERG readings, where the amplitude 
of responses was increased, together with shortening of times-to-peak, and retinal 
conduction times. These changes suggest the effects of Citicoline to be both at retinal, and 
at post-retinal visual pathway level.  Beyond these initial clinical trials, the same group has 
presented eight-year follow up data with intramuscular Citicoline treatment, which appears 
to suggest stabilisation, or even improvement of glaucomatous visual dysfunction as 
measured by VF stabilisation, and improvements in PERG and VEPs [61]. Long term data 
with topical Citicoline is awaiting publication [62], while oral Citicoline has also been found 
to reduce the rate of VF progression in POAG patients [63], and improve visual pathway 
function as measured by electrophysiological tests [64].  
 
Memantine 
Memantine is an non-competitive glutamate antagonist, which blocks excessive NMDA 
activity, and has been approved as a treatment for moderate-to-severe Alzheimer’s disease 
[65]. Studies have explored the potential for Memantine in the treatment of glaucoma as a 
potential neuroprotectant; Pre-clinical animal studies have demonstrated Memantine to 
have a neuroprotective effect on RGC death in a rat OHT model, as well as an optic nerve 
injury model [66]. Another animal study suggested that Memantine treatment at the early 
phases of the glaucomatous process appears to prevent neuronal injury in the retina [67].  
 
These promising animal study results are yet to be replicated in human studies however, 
with two phase 3 clinical trials involving Mementine in glaucoma patients failing to publish 
results to confirm its neuroprotective effects thus far. This maybe disappointing, but other 
second generation Memantine derivatives are in development and may be shown to be 
beneficial for glaucoma patients in the future [68]. 
 
The difficulty in translating animal study and early clinical trial results to clinical practice in 
glaucoma and other neurodegenerative disease is not an uncommon problem [69]. This may 
in part be due to difficulties in quantifying disease progression in a slow progressing, 
multifactorial disease. In neuroprotection studies for example, where the focus is the 
prevention of functional damage in patients, recruitment of patients with established 
disease may not allow the demonstration of maximum effects of the agent being tested. 
Another stumbling block is that currently one of the common measurable outcomes in 
glaucoma studies is based on visual field progression. This measurement method is limited 
by patient performance variability, learning effect, and more importantly may not be 
sensitive enough to detect small treatment effects in neuroprotection trials. Detecting these 
subtle effects would require very large cohorts, and possibly a lengthy trial to demonstrate 
therapeutic benefits for a slowly progressive disease.  
  
Novel therapies, and neuroprotection in glaucoma treatment: 
As a result of the search for IOP independent approaches to glaucoma treatment in recent 
years, there has been an explosion of exciting research exploring potential molecules 
contributing to the aetiology of glaucomatous optic neuropathy. The importance of this on-
going research and development in neuroprotection is highlighted by patients who’s disease 
progresses to blindness despite maximally tolerated hypotensive medications or surgical 
procedures.  Quite simply, the emphasis is on: 
- Neuroprotection, preventing or delaying the apoptosis of RGC’s 
- Neuro-recovery, reversing the process of RGC apoptosis 
We have summarised the various aetiologies leading to the endpoint of glaucomatous optic 
neuropathy and the studies citing evidence in targeting these mechanisms in Table 1. These 
studies are discussed in further details in the following sections.  
 
Table 1: 
Mechanism  Mediators & 
targets 
Pre-clinical studies 
Clinical studies  
Smooth muscle 
contraction at the 
Trabecular Meshwork 
ROCK  Honjo M [70], Rao PV 
[71], Delaney Y [72], 
Grieshaber MC [73], 
Kandabashi T [74], 
Chrissobolis S [75], 
Kitaoka Y [76], Bertrand 
J [77], Bertrand J [78], 
Honjo M [79], Okumura 
N [80], Waki M [81], 
Thieme H [82] 
Tanihara H [83], 
Nakajima E [84], 
Wang R [85], 
Mizuno K [86], Chen 
J [87] 
Ischaemia due to 
vasoconstriction 
ET, Adenosine, 
RAS 
Renieri G [88], 
Ehrenreich H [89], 
Yagami T [90], Yagami T 
[91], Zhang M [92], 
Galvao J [93], Wang RF 
[85], Inoue T [94], Yang 
H [95], Cullinane AB 
[96], Kramkowski K [97], 
Santos RAS [98], 
Vaajanen A [99] 
Costagliola C [100] 
Pleomorphic activity  
NO Nathanson JA [101], 
Garcia E [102] 
 
Apoptosis 
Caspases and 
PERK/CHOP 
McKinnon SJ [103], Guo 
L [104], Doh SH [105] 
 
Immune-modulated 
neurotoxicity 
Exaggerated 
complement 
response 
Bonifati DM [106], Tezel 
G [107], Ding QJ [108], 
Howell GR [109] 
 
Oxidative stress & 
mitochondrial 
dysfunction 
ROS mediated 
damage 
Osborne NN [110], Tezel 
G [107], Ju WK [111], 
Tezel G [112], Huang J 
[113], Barber AJ [114], Li 
J [115] 
 
 
Table 1: Various mechanisms leading to the endpoint of glaucomatous optic neuropathy and 
the studies citing evidence in targeting each mechanism 
 
Rho-associated coiled coil-forming protein kinase (ROCK) Inhibitors: 
A number of studies have explored Rho signalling in the TM; Rho is a GTPase enzyme 
involved in cytoskeletal rearrangement and smooth muscle contraction, being facilitated 
further down the signalling pathway by specific GTPases called Rho-associated coiled coil-
forming protein kinase (ROCK) [116]. Two human isoforms of these serine/threonine kinases 
are present, ROCK 1, and ROCK 2, being expressed in both the CM and TM. Specifically, 
ROCK is involved in myosin light chain (MLC) phosphorylation, with the cycle of 
phosphorylation/dephosphorylation responsible for contraction and relaxation of smooth 
muscle. Manipulation of this process represents a novel form of anti-hypertensive drug and 
indeed, both laboratory & animal studies have proposed the following mechanisms of 
action [70–80]: 
o Improving blood flow to the ON 
o Neuroprotection of healthy ganglion cells 
o Relaxing TM tissue 
The predominant mechanism by which ROCK inhibtors exert their clinical effects are 
decreasing outflow resistance by modulating cytoplasmic fibres [117], and hence increasing 
the outflow via the conventional route. It is also important to note that as well as via ROCK 
mediated signalling, phosphorylation of this MLC complex is achieved by calcium 
mobilisation [118]. 
 
A multitude of animal studies have shown that one ROCK inhibitor, Y-39983 relaxes both the 
CM and TM, leading to a reduction in IOP [70,71,81,82]. Tokushige at al compared Y-39983 
to another ROCK inhibitor Y-27632 in both albino rabbits and cynomolgus monkeys [119]. Y-
39983 proved to be the more stable compound of the two, inhibiting ROCK more potently, 
and clinically resulting in an increased outflow and hence reduced IOP [119]. Interestingly, 
whilst the maximal IOP reduction achieved in rabbits was 13.2 +/- 0.6 mmHg, it was 
appreciably lower in monkeys (2.5 +/- 0.8 mmHg). The author suggested this may be the 
case for a variety of reasons including reduced blinking rates in rabbits (hence less clearance 
of Y-39983), and a difference in the inter and intra-species expression of ROCK or its 
substrates, suggesting that in clinical administration individuals may have varying responses 
[119]. The following year, Tanihara et al used various concentrations of ophthalmic solution 
of Y-39983 in a randomised, double blind, phase one trial in humans [83]; It was elucidated 
that the once daily 0.1% group had an IOP reduction of 3mmHg at four hours. 
 
Nakajima et al performed PCR analysis in both monkeys and humans, revealing that in both 
species greater levels of mRNAs for ROCK and ROCK substrates can be found in the TM 
compared to CM, although this TM versus CM discrepancy was not as high in humans as it 
was in monkeys [84]. As a result, the over-riding effect of Y-39883 led to relaxation of TM in 
monkey compared to modest relaxation in CM, suggesting that TM was the principle site for 
regulating IOP by manipulation of the ROCK-signalling pathway. This subverts the previously 
mentioned side-effects commonly encountered with pilocarpine, namely changes in 
accommodation and meiosis [84]. 
 
Some reports have described a topical formulation of AR-12286 that has more selectivity for 
ROCK inhibition than Y-39983. A topical preparation of AR-12286 applied to non-human 
primates reduced IOP in normotensives by increasing trabecular outflow [85]. Whilst phase 
two studies revealed maximum reduction of 28% noted in twice daily 0.25% AR-12286 
application, the long-term tolerability profile and reduction of IOP in humans is not 
known[85]. In fact, phase two studies have been undertaken successfully for K-115 [86] , Y-
39983  [83], INS-117548 and RKI-983, with the latter shown to be inferior to, and causing 
more adverse events in comparison to latanoprost (IOP lowering of 4.8 versus 6.7 mmHg at 
day 29) [87]. 
 
Renin-angiotensin system (RAS): 
Aside from ROCK related signalling cascades, the renin-angiotensin system (RAS) pathway 
exerts an important role in IOP control. Ocular blood flow depends on both perfusion 
pressure (mean arterial blood pressure) and resistance to flow, determined by the vascular 
calibre of the arterioles and capillaries, which can be influenced by dilators and constrictors 
such as RAS [120]. Evidence has accrued that local RAS exists in the human eye and that 
systemic anti-hypertensive drugs can act on the ocular RAS pathway to reduce the IOP [99]. 
For example, topical olmesartan in cynomolgus monkeys given twice daily reduced IOP by 
6.9mmHg at day 5 [121]. Other examples in the literature include publications 
demonstrating that intra-cameral administration of Angiotensin II diminishes uveoscleral 
out-flow in anaesthetised cats [94], and oral ACE-inhibitor (ACE-I) and angiotensin receptor 
blocker Losartan causes reduced IOP in human subjects [100].  Moreover, angiotensin 
receptor blockers have also been demonstrated to be neuroprotective against ganglion cell 
loss in a rat chronic glaucoma model [95]. Many RAS components have been shown in 
cultured human ciliary body cells (CB) and TM cells [96], hence affecting both production 
and outflow. Similar to systemic processing, local angiotensin can be catalysed by enzymes 
other than angiotensin converting enzyme-one (ACE1), including chymase or cathepsin G 
[97]. Unlike systemic RAS, there is a more integral role for the enzyme ACE2 and its product 
angiotensin, which has been shown to activate the Mas receptor and act opposite to 
angiotensin II by increasing outflow and reducing IOP [98]. Vaajanen et al noted the 
expression of this novel angiotensin receptor Mas in the CB and retina, with ACE2 present in 
ocular structures [99]. ACE-Is act to activate the nitric oxide (NO) pathway and reduce the 
formation of the vasoconstrictive peptide endothelin-1 (ET-1) [99]. Other potential agents 
that could be putative therapeutic targets include compounds that increase ACE2, and 
hence increase production of Ang and Mas receptor agonists. 
 
Endothelin-1 (ET-1) Pathway: 
As alluded to above, the homeostasis achieved by the balance between ET-1 and NO is 
important in the pathogenesis of glaucoma. ET-1 has been postulated as an important 
player as it has the combined role of inducing ON ischaemia through vasoconstriction, and 
glial cell proliferation [122], as well as by contributing to congestion of aqueous egress 
through the TM [123]. It is a twenty-one amino-acid peptide, produced by cleavage from 
preproendothelin through converting enzymes. ET-1 is naturally present in the eye, 
produced by non-pigmented ciliary epithelium. Choritz et al performed a small study looking 
at ET-1 in the aqueous humour of 35 humans eyes with POAG, and 21 eyes with 
pseudoexfoliation glaucoma (PXFG) [124]; They showed that aqueous humour ET-1 was 
significantly elevated in glaucomatous eyes in comparison to controls, while  there was no 
correlation between plasma ET-1 with that found in aqueous humour. Renieri et al 
proposed that calcium independent signalling is an important cascade mediated by ET-1 
[88]; In a bovine population, the authors created a calcium independent environment by 
administrating the buffers EGTA and BAPTA-AM. Subsequent application of the ET-1 
receptor antagonists BQ123 significantly reduced the contraction of smooth muscles in the 
TM [88]. Interestingly, ET-1-induced contraction was abolished in the presence of Y-39983, 
suggesting that the ET-1 pathway leading to muscle contraction is independent of Ca, but 
reliant on the ROCK signalling cascade. Whilst both ET-A and ET-B receptors are involved, 
the former was associated with a greater affect on contractile force [88]. 
 
As well as being a vasoconstrictive peptide, ET-1 also acts as an anti-apoptotic agent. 
Ehrenreich et al showed that when exerting its affect via the ET-B receptor, ET1 is associated 
with neuronal survival in the brain [89]. A cerebrovascular accident model revealed that 
phospholipase A2 is expressed in the cerebral cortex and its activation causes an 
intracellular influx of calcium to mediate neuronal cell death. The authors postulated 
correctly that the ET-B receptor agonist ET3 administration would inhibit the phospholipase 
A2 signalling cell death mechanisms. Furthermore, blockers of L-type voltage-dependent 
calcium channel (L-VSCC), not only suppressed the calcium influx, but also exhibited 
neuroprotective effects [90]. 
 
Incidentally, Yagami et al 2002 showed that the phospholipase A2 liberated in any cerebral 
ischaemic insult causes cell death in a dose-dependent manner above 0.1 micrometer, 
predominantly by the apoptotic pathways [91]. The author aimed to assess this putative 
role in toxicity by inducing middle cerebral artery occlusion in rat models and subsequent 
evaluation of cortical neurons. It was shown that the phospholipase A2 inhibitor indoxam 
not only negated the toxicity effect of phospholipase A2, but it also reduced the overall 
neurodegeneration in the cortex [91]. 
 
Nitric Oxide (NO): 
The situation is not as simple as pure interplay between the vasoconstrictor ET1 and the 
vasodilator NO, as in the presence of certain environments the latter can act as a source of 
reactive oxygen species and lead to lipid peroxidation. Hence, the exact role that NO plays 
after neural injury and in the pathogenesis of glaucoma per se is controversial, with studies 
being contradictory regarding its role as either protective or destructive. It is likely that the 
exact role it exhibits depends on the environment it is exposed to and the nature of the up-
regulating enzymes. For instance, Nathanson et al showed that immunological analysis of 
the outflow pathway revealed an abundance of NOS-3 receptors, which typically are found 
in human vascular endothelium rather than cerebral tissue [101]. Further biochemical 
analysis confirmed NADPH led production of NO, concentrated at sites of outflow, 
specifically the longitudinal fibers in the CM, TM, and Schlemm’s canal [101]. Conversely, 
Garcia et al 2012 administered neural-derived peptides Cop-1 and A91, liberating T-cells 
activated to Th2-type immune response, capable of counteracting NO production [102]. This 
was seen when glial cells were cultured with these activated T-cells in vitro, leading to the 
reduced production of NO. Furthermore, the iNOS mRNA expression significantly 
diminished, iNOS being the most important enzyme in NO synthesis after neuronal injury 
[102]. 
 
Adenosine agonists and cannabinoids: 
There are many other mediators that could potentially play a pivotal role in the aetiology of 
glaucoma, and numerous potential pathways that could be manipulated in glaucoma 
management. The endogenous purine analogue adenosine acts via four different receptor 
types, with Zhang et al showing that RGC’s express predominantly the A3 variant [92]. 
Currently, trials are on-going with the following mediators: INO-8875/PJ-875 (A1 agonist), 
OPA-6566 (A2A agonist), ATL-313 (A2A agonist) and CF-101 (A3 agonist), with Galvao et al 
recently publishing that the CF-101 decreased the number of apoptotic RGCs, thereby 
increasing RGC survival in a rat models of cell degeneration induced by excitotoxicity [93]. 
The authors do however caution the effect of CF-101 may be different both in varying 
experimental models and concentrations used [93]. 
 It is known that G-protein coupled activation of CB1 and CB2 receptors through 
tetrahydrocannabinol can reduce IOP [125]. The evidence is conflicting as to whether 
pursuing this as a clinical modality is a worthwhile venture; A study by Novartis in 2007 
revealed that it’s effect was equivalent to placebo and the company had no plans to take 
the research further [126]. Conversely, a study by Chien et al revealed that twice daily 
administration in cynomolgus monkeys led to a reduction in IOP of 3.4mmHg [127]. 
 
 
  
Glaucoma as a neurodegenerative disease: Apoptosis 
 
Comparisons are often drawn between glaucoma and a host of other neurodegenerative 
diseases. Of these conditions, similarities found between glaucoma and Alzheimer’s disease 
(AD) are among the more frequently cited. Like AD, glaucoma has an increased incidence 
with age, being progressive in nature [128]. There is also evidence to suggest comorbidities 
with the co-incidence of AD and glaucoma [129,130], although this is controversial [131]. 
 
Neuronal cell death is the hallmark feature in all neurodegenerative diseases such as 
glaucoma and AD. In glaucoma, visual loss is due to RGC death via apoptosis, and therefore 
RGC apoptosis needs to be curbed in order for progression of this neurodegenerative 
disease to be halted. In AD, neuronal cell death in the cerebral cortex is caused by the triad 
of accumulation of extracellular beta-amyloid protein, increase in intracellular tau protein, 
and neurofibrillary tangles [131]. Some studies have alluded a parallel molecular basis of 
RGC death in glaucoma; caspases are heterodimers that are central in neuronal cell death, 
through mechanisms which include cleavage of structural elements, and degrading DNA 
repair enzymes [132]. Amyloid precursor protein (APP), which is vital for homeostasis of the 
synaptic junction in neurons, contains a cleavage site for the protein caspase-3. McKinnon 
et al showed that in rat models of glaucoma, caspase-3 mRNA and caspase-3 mediated APP 
cleavage product was increased in comparison to controls [103]. The cleavage product in 
turn acts to up-regulate amyloid beta, which is the major constitute of senile plaques in 
Alzheimer’s disease, but is also postulated to be contributory to the neurodegenerative 
disease glaucoma [103]. Guo et al revealed that amyloid beta (A) is elevated in 
experimental glaucoma models, and that exogenous administration of A induces RGC 
apoptosis [104]. The authors hypothesized interventions that target A might reduce the 
levels of RGC apoptosis and tested the administration of a -secretase inhibitor (which 
blocks initial step of APP cleavage in the amyloidgenic pathway), CR (which blocks A 
aggregation and toxicity) and Aab (which increase A clearance); they noted that 
compared with Aab single therapy, triple therapy was far more effective in the mean 
reduction of RGC apoptosis (74% versus 84% respectively) [104]. 
 
When a cell is severely stressed, apoptosis is induced by the endoplasmic reticulum (ER) 
stress pathway. This is mediated by factors including C/EBP homologous protein (CHOP) 
[133,134]. Doh et al studied ER stress, the CHOP pathway, and glaucoma using the chronic 
injury model, inducing glaucoma in rats by cauterizing the episcleral veins; It was shown that 
chronically raised IOP up-regulated the PERK/CHOP pathway inducing apoptosis (PERK  
being expressed one-week post induction of glaucoma, and CHOP peaking at 4 weeks) [105]. 
 
Protein mis-folding is thought to be the common underlying key feature shared by AD and 
pseudoexoliation glaucoma; In AD, the soluble amyloid-beta protein is transformed to 
harmful fibrillar amyloid-beta plaques by what is thought to be a mis-folding mechanism. In 
psudoexfoliation glaucoma, abnormal fibrillar extracellular material deposits are found in 
ocular structures and systemic tissues [135]. These deposits cause secondary glaucoma by 
increasing resistance to aqueous outflow via the trabeceular meshwork pathway. Analysis of 
these exfoliation materials has revealed a complex abnormal metabolism of 
glycosaminoglycans, non-collagenous basement membrane components, and epitopes of 
the elastic fibre system such as fibrillium [136,137]. The heavily cross-linked nature of these 
proteins, and their assembly in to a supra-molecular fibrillar structure implies an underlying 
mis-folding mechanism similar to that seen in AD [131]. Misfolded amyloid-beta is also 
found surrounding RGCs in POAG, likely as a result of cellular stress [131]. 
 
A caveat from the preceding section is that whilst apoptosis is an important causative factor 
for vision loss in glaucoma, other independent axonal degeneration mechanisms also exist. 
Perhaps the most eloquent paper depicting this is Libby et al 2005 using BAX (a pro-
apoptotic gene) knock out mice [138]; The authors elegantly demonstrated that while BAX 
deficiency protected RGCs from apoptosis in an inherited glaucoma model, it did not prevent 
axonal degeneration, leading the authors to conclude that distinct somal and axonal 
degeneration pathways are at play in this model of glaucoma [138]. These findings highlight 
the importance of a quest for treatment modalities that also target axonal degeneration.  
 
 
Immune-modulation & oxidative stress 
In the physiological neuronal environment, the innate immune system serves to provide 
immunity against pathogens and remove dying host cells, thereby minimising inflammation 
and reducing the risk of developing autoimmunity [139]. The classic complement system is 
initiated by C1q [140]. In chronic neurodegenerative conditions however, there is an up-
regulation of pro-inflammatory cytokines, which act to propagate the immune response and 
thus lead to sustained neurotoxicity [106]. Tezel et al demonstrated this phenomenon in 
glaucoma by finding the up-regulation of complement factors and down-regulation of their 
inhibitors in glaucomatous RGC’s using proteomic analyses [107]. 
 
In experimental glaucoma, RGC’s undergo accelerated apoptosis by activation of the 
classical complement system, and Ding et al determined that this could be achieved without 
the need of immunoglobulins (Ig), with the complement cascade initiating RGC damage by 
C1q binding to other ligands such as 21 integrin [108]. A mouse model genetically devoid 
of the ability to rearrange and recombine Ig and T-cell receptors,  was subjected to raised 
IOP, and found to have no difference in loss of RGC’s compared to control models subjected 
to raised IOP at 28 days [108]. Howell et al used DBA/2J mice, a widely used mouse model of 
glaucoma, and demonstrated that combined blockade of the endothelin and classical 
complement pathway, by administrating Bosentan (dual ET-A and ET-B receptor antagonist) 
led to significantly more RGC survival than blockade of one pathway alone [109]. 
 
Increasing evidence is accumulating that oxidative stress and mitochondrial dysfunction 
have roles in neurodegenerative disease, including RGC apoptosis. Whilst the exact 
mechanism are not certain, it is likely that reactive oxygen species (ROS) are central in 
causing cellular damage [112,141]. In essence, if ROS production exceeds the anti-oxidant 
capacity of the mitochondria, RGCs are likely to activate the apoptotic pathways. Ju et al 
used electron microscopy analyses in glaucomatous ONH, to demonstrate IOP induced 
mitochondrial changes including fission, matrix swelling and abnormal cristae depletion 
[111]. It is therefore logical that the mitochondria are effective therapeutic targets to 
reduce oxidative stress on the cell in a bid to reduce RGC apoptosis. Tezel et showed that 
reducing ROS generation could protect RGC’s from apoptosis [142], while a host of in vivo 
studies have demonstrated that the anti-oxidant SS-31 has the capacity to reduce oxidative 
damage and indeed promoted anti-apoptotic protein expression [113–115]. The need for 
these specific inhibitors is due to the fact that systemic anti-oxidants like vitamin E and C 
lack the ability to cross the blood-retina and blood-brain barriers. 
 
Some groups have hypothesised that glaucoma is primarily due to compromised blood 
supply to the optic nerve head, resulting in mitochondrial energy supplies not being met in 
such an ischaemic environment. The mitochondria adapt by suppressing the energy 
sensitive cellular processes, predominantly by inhibiting mTORC1 [143,144]. Many potential 
stimuli have been implicated in the aetiology of RGC apoptosis in glaucoma. Cultured retinal 
cells exposed to short wave-length blue light undergo apoptosis, with the up-regulation of 
REDD1 causing the dysfunction. Del Olmo-Aguado et al showed that inhibiting the affect of 
REDD1 with rapamycin ameliorated cell death [145], a finding confirmed in vivo by Kitaoka 
et al who used intra-vitreal injections of rapamycin in a rat model to reduced optic nerve 
degeneration [146]. 
 
A variety of toxic materials liberated locally from cells such as astrocytes, can lead to the 
inability of mitochondria to maintain normal function [110]. Co-culture of RGC’s and glial 
cells showed that TNF- is secreted by stressed glial cells, leading to apoptotic death of 
RGCs [147], while homocysteine release leads to RGC loss secondary to dysregulation of 
mitochondria [148]. It therefore stands to reason that potential interventions targeting 
mitochondrial protection could have great clinical implications; these could include spectral 
filters on spectacles to prevent photo-toxicity, or suppression of oxidative stress, for 
instance by superoxide dismutase (SOD2) gene delivery [149]. 
 
 
Stem cell therapy: 
Glaucoma clinics are full of optimistic patients expressing hope for new scientific 
breakthroughs that can relate to clinical practice and at the cornerstone of this is always a 
conversation about prevention of progression and advances in regeneration, namely stem 
cell therapy. 
 
Several groups have shown that impaired retrograde transport of neurotrophic factors at 
the level of the optic nerve is important in the aetiology of glaucoma, and it is thought that 
stem cell transplantation can ameliorate neurodegenerative conditions in the CNS, partly 
due to neurotrophic factor secretion [150,151]. Schori et al have shown that autoimmune T-
cells directed against CNS associated myelin antigens protect neurons from secondary 
degeneration. This paper advocated the passive and active immunization against co-
polymer (Cop-1), as a substitute for natural myelin Ag, for neuroprotection in optic nerve 
pathology simulated in mice by the intra-vitreal injection of glutamate [152]; The number of 
surviving RGCs in the group immunized 10 days prior with emulsified Cop-1 was far higher 
than controls. This pattern was observed even if the immunization was on the day of 
glutamate insult, but no longer seen if immunisation occurred two weeks after the insult. 
This reduction in loss of RGC was independent of effects on IOP [152]. Johnson et al looked 
at intra-vitreal delivery of local or systemic femur bone marrow-derived mesenchymal stem 
cells (MSC) into a rat model of laser-induced glaucoma [153]; They showed that this 
technique of administration ensured that the majority of cells remained within the vitreous 
cavity, whilst a small number migrated within the nerve fibre layer. Although the primary 
outcome measure was ON damage, and the survival of RGC bodies was not directly 
investigated, the results were statistically significant for RGC axon survival, which was lost 
when the delivery method was intra-venous [153]. Excitingly, Ng et al are currently 
undertaking a clinical trial delivering bone marrow derived cells in Florida [154]. 
 
Neuronal regeneration: 
Sadly, inherent to neurological cells is their lack of ability to repair and regenerate in 
response to insults. Although in their natural habitat RGC’s lack the propensity to regrow 
injured axons, various authors have begun to describe the process of regeneration and 
offered hope to facilitate this process. Indeed, Jo et al (1998) showed that injured 
mammalian RGCs exposed in culture to the molecular micro-environment of the peripheral 
nervous system, leads to regenerated growth [155]. Whilst many neurotrophic agents have 
been suggested, the only proven molecules to be described are ciliary neurotrophic factor 
(CNTF) and leukaemia inhibitory factor (LIF), both leading to the up-regulation of a marker 
for high axon regeneration growth associated protein 43 (GAP-43), confirmed by Western 
blots [156]. GAP-43 is usually undetectable in physiological conditions, but is strongly up 
regulated in conditions of damage and subsequent attempts to regenerate. Cultivating RGCs 
with CNTF and LIF led to increasing the percentage of cells with axons greater than five cell 
diameters fivefold over controls, with the effect being more dramatic the longer the cells 
were cultured [156]. 
 
Whilst not yet at the clinical trial stages, nerve growth factor (NGF) is generating a growing 
amount of interest. The premise for its use in glaucoma stems from encouraging results 
seen following its intra-cerebral application in patients with Alzheimer’s and Parkinson’s 
diseases [157,158]. Lambiase et al administered intra-vitreal NGF in a rat glaucoma model, 
leading to lower anti-TUNEL staining, as a marker of apoptotic cell death, and higher Bcl-
2/Bax ratio in the treatment arm, both indicating greater RGC survival [159]. In the same 
paper, the group also reported that topical murine NGF 200 g/mL given to human patients 
with advanced glaucomatous optic neuropathy led to sustained improvements in neuronal 
function after three months, as demonstrated by electrophysiological tests [159]. 
 
Other neurotropic factors with as yet no proven evidence of inducing neuro-regeneration 
include BDNF, neurotrophin-3 & 4 (NT3, NT4), insulin-like growth factor (IGF), basic 
fibroblast growth factor (bFGF) and neuregulins. Many authors have studied the specific 
neurite growth inhibitors myelin associated glycoprotein (MAG), Nogo-A, and Omgp, which 
exert their effects on the common receptor Nogo-receptor (NgR) [160–162]; Su et al 
induced optic nerve crush injury in NgR knock-out mice and elucidated that GAP-43 was 
highly expressed, when compared to control subjects. Fischer et al showed that once 
activated by macrophage-derived factors, RGC’s can regenerate their axons for vast 
distances through the distal optic nerve [163]; The authors administered RGC’s in-vitro with 
a truncated dominant negative form of NgR via an adeno-virus vector and noted a fortnight 
after the induced injury, the dominant negative group had seventy-five times more axons 
extending more than one millimetre beyond the site of injury compared to controls 
expressing NR (n=5) [163], suggesting that NgR antagonists are putative therapeutic targets. 
 
  
Conclusions and future perspective: 
Glaucoma is a complex neurodegenerative process with a large number of mediators 
eliciting key roles in its pathogenesis. While a plethora of medical and surgical treatments 
currently address the only modifiable risk factor, IOP, there is still a subset of patients 
whose disease inevitably progresses despite treatment.  
 
The neuroprotective and neuroregenerative agents discussed here, some of which are 
already commercially available, may take the management of glaucoma to a new direction 
and complement the currently established IOP based treatment paradigm. This may also 
impact the way we manage glaucoma at the clinical practice level, as the focus will move 
beyond merely IOP control. Other measurement parameters such as electrophysiology, 
visual field testing, as well as retinal and neuroimaging may become increasingly important 
in the monitoring and management of the disease as our treatment modalities aim to 
address more than just IOP in the future. 
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